(4S)-4-benzyl-3-{3-[4-(benzyloxy)phenyl]propanoyl}-1,3-oxazolidin-2-one | 244211-29-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: (4S)-4-benzyl-3-{3-[4-(benzyloxy)phenyl]propanoyl}-1,3-oxazolidin-2-one
• 英文别名: 4-(S)-benzyl-3-[3-(4-benzyloxy-phenyl)-propionyl]-oxazolidin-2-one；(4S)-4-benzyl-3-[3-(4-phenylmethoxyphenyl)propanoyl]-1,3-oxazolidin-2-one
• CAS: 244211-29-8
• 化学式: C₂₆H₂₅NO₄
• 分子量: 415.489
• InChiKey: ABKKGYBGPZDODV-QHCPKHFHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.1
• 重原子数：
  31
• 可旋转键数：
  8
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.23
• 拓扑面积：
  55.8
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (4S)-4-benzyl-3-{3-[4-(benzyloxy)phenyl]propanoyl}-1,3-oxazolidin-2-one 在 palladium on activated charcoal 氢气 、 三氟乙酸 、 lithium diisopropyl amide 作用下， 以 四氢呋喃 为溶剂， 生成 (R)-4-((S)-4-Benzyl-2-oxo-oxazolidin-3-yl)-3-(4-hydroxy-benzyl)-4-oxo-butyric acid
  参考文献：
  名称：

  Hybridization of non-sulfonylurea insulin secretagogue and thiazolidinedione-derived insulin sensitizer

  摘要：

  Hybrid compounds of non-sulfonylurea insulinotropic agents and thiazolidinedione-derived insulin-sensitizing agents were designed and synthesized. The benzylidenesuccinic acid derivative 24 was equal both to nateglinide in potency of insulin-releasing activity and to pioglitazone in insulin-sensitizing activity. (C) 2000 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(00)00491-1
• 作为产物：
  描述：

  、 (S)-4-苄基-2-唑烷酮 在 正丁基锂 作用下， 以 四氢呋喃 、 正己烷 为溶剂， 反应 0.25h， 以82%的产率得到(4S)-4-benzyl-3-{3-[4-(benzyloxy)phenyl]propanoyl}-1,3-oxazolidin-2-one
  参考文献：
  名称：

  Aldol / Curtius策略合成生物碱酪氨酸

  摘要：

  由4-羟苯基丙酸（5）和内消旋二醇9制备了含有邻位抗氨基醇亚基的生物碱酪氨酸（2）。二醇desymmetrization后9和合适的保护基处理，一个末端延长通过Claisen重排引起烯酸ENT - 15。在另一端缺失的碳可以通过使用格氏引发剂/溴化亚铜·SMe的掺入2最终导致醛ENT - 22。酸5和醛衍生的酰化恶唑烷酮32ent - 22在醛醇缩合反应中合并。随后在羧基上的库尔修斯重排提供了酪氨酸（2）的氨基功能。在概念验证研究中，相同的策略用于制备酪氨酸类似物28。

  DOI：

  10.1016/j.tet.2010.02.034

文献信息

• Melanocortin receptor ligands
  申请人：Ebetino Hallock Frank

  公开号：US20060128613A1

  公开（公告）日：2006-06-15

  Disclosed are MC-4 and/or MC-3 receptor ligands, the ligands having a structure according to Formula (I): wherein R 2 , R 4 , R 4′ , R 5 , R 6 , R 6′ , R 7 , R 8 , R 8′ , R 9 , R 9′ , R 10 , Ar, Z 1 , Z 2 , Z 3 , X, B, D, p, q, r and s are as described in the specification and claims, and optical isomers, diastereomers or enantiomers thereof; pharmaceutically-acceptable salts, hydrates, and biohydrolyzable esters, amides or imides thereof. Also disclosed are pharmaceutical compositions comprising the ligands of Formula (I), as well as methods of treating diseases mediate by the MC-4/MC-3 receptors, as described in the Detailed Descriptions section of the specification.

  公开了MC-4和/或MC-3受体配体，该配体具有按照式（I）的结构：其中R2、R4、R4'、R5、R6、R6'、R7、R8、R8'、R9、R9'、R10、Ar、Z1、Z2、Z3、X、B、D、p、q、r和s如说明书和索赔中所述，以及其光学异构体、二对映异构体或对映体；药用盐、水合物和生物水解酯、酰胺或亚酰胺。还公开了包括式（I）配体的药物组合物，以及治疗由MC-4/MC-3受体介导的疾病的方法，如说明书的详细描述部分所述。
• Nonpeptidic SH2 inhibitors of the tyrosine kinase ZAP-70
  作者：Chi B. Vu、Evelyn G. Corpuz、Selvaluxmi G. Pradeepan、Shelia Violette、Catherine Bartlett、Tomi K. Sawyer

  DOI：10.1016/s0960-894x(99)00524-7

  日期：1999.10

  The synthesis of a series of 1,2,4-oxadiazole analogs is discussed along with their ZAP-70 SH2 inhibitory activity. The tyrosine moiety in the original series has been replaced with nonpeptidic functional groups without a substantial loss of binding affinity. (C) 1999 Elsevier Science Ltd. All rights reserved.
• MELANOCORTIN RECEPTOR LIGANDS
  申请人：THE PROCTER & GAMBLE COMPANY

  公开号：EP1409540A2

  公开（公告）日：2004-04-21
• [EN] MELANOCORTIN RECEPTOR LIGANDS<br/>[FR] LIGANDS DE RECEPTEURS DE LA MELANOCORTINE
  申请人：PROCTER & GAMBLE

  公开号：WO2002026774A2

  公开（公告）日：2002-04-04

  Disclosed are MC-4 and/or MC-3 receptor ligands, the ligands having a structure according to Formula (I): wherein R?2, R4, R4', R5, R6, R6', R7, R8, R8', R9, R9', R10, Ar, Z1, Z2, Z3¿, X, B, D, p, q, r and s are as described in the specification and claims, and optical isomers, diastereomers or enantiomers thereof; pharmaceutically-acceptable salts, hydrates, and biohydrolyzable esters, amides or imides thereof. Also disclosed are pharmaceutical compositions comprising the ligands of Formula (I), as well as methods of treating diseases mediate by the MC-4/MC-3 receptors, as described in the Detailed Descriptions section of the specification.